

Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review

Weekly Summary Tables

Updated December 4, 2025

Prepared by:

International Vaccine Access Center,
Johns Hopkins Bloomberg School of Public Health

and

World Health Organization

and

Coalition for Epidemic Preparedness Innovations



World Health
Organization



For comments or questions, please contact: Anurima Baidya at abaidya1@jhmi.edu or
Karoline Walter at kwalte21@jhmi.edu.

INSTRUCTIONS FOR ACCESSING CONTENT:

- This PDF contains attachments. To access the attachments, you will first need to download the PDF and open it on your computer. Once open, you can click on any section in the table of contents to access a particular section, and a new PDF will open with that content.
- Adobe Acrobat Reader can be downloaded free of charge [here](#).
- To open a specific section (which will open a new PDF) without closing the TOC, you may need to update your preferences.
 - In Adobe Acrobat, go to 'Edit' → 'Preferences.'
 - In the 'Documents' category, unselect 'Open cross-document links in the same window.'
 - Alternatively, you can click directly on the attachments in the navigation panel on the left. To open the attachments panel, click on the paper clip icon on the left navigation/task bar.

Notes to readers:

- Yellow highlights indicate a study was conducted during an Omicron dominant period.
- Excluded studies conducted during the Omicron period are noted in **red** text in sections 1.2 and 2.1.
- Second booster doses are indicated in Section 2 by **blue** text in the 'Vaccine Product' column.
- Bivalent booster doses are indicated in Section 2 by **turquoise** text in the 'Vaccine Product' column.
- Monovalent XBB.1.5 boosters are indicated in Section 2 by **orange** text in the 'Vaccine Product' column.
- Monovalent JN.1 boosters are indicated in Section 2 by **brown** text in the 'Vaccine Product' column.
- Monovalent KP.2 boosters are indicated in Section 2 by **green** text in the 'Vaccine Product' column.
- When not otherwise specified, mRNA vaccines refer to the original monovalent mRNA vaccines.
- The term 'any' is used with mRNA vaccines to indicate any manufacturer of mRNA vaccines (i.e. Moderna or Pfizer BioNTech).

TABLE OF CONTENTS

1. Summary of Study Results for Post-Authorization COVID-19 Primary Series Vaccine Effectiveness
 - 1.1 Inclusion criteria for VE studies
 - 1.2 Studies that do not meet criteria
2. Summary of Study Results for Post-Authorization COVID-19 Booster Dose Vaccine Effectiveness
 - 2.1 Booster studies that do not meet criteria
3. Summary of Study Results for Primary Series COVID-19 Primary Series Vaccine Effectiveness against Transmission
4. Summary of Study Results for Primary Series COVID-19 Booster Dose Vaccine Effectiveness against Transmission
 - 4.1 Transmission studies that do not meet criteria
5. Review Papers and Meta-Analyses